Loading...

RZLT REZOLUTE INC Business Restructuring 8-K Filing

RZLT

RZLT

REZOLUTE INC

(RZLT)

2023 8-K

Show Summary

Summary

Investor Meetings

Private Offerings

Financial Statements

Equity Offerings

Equity Offerings

Clinical Trials

New Director Appointment

Financial Results

Clinical Study Update

FDA Designation

Q1 Financial Results

Financial Results

FDA Approval Update

FDA Clearance and Corporate...

Private Placement

Public Offering

Phase 2 Clinical Study Results

Annual Meeting Voting Results

Earnings Reports

Agreement and Accounting Fi...

Compliance regained with Na...

Earnings Reports

Appointment of Chief Financ...

Clinical Study Updates

Earnings Reports

Earnings Reports

Clinical Program Update

Investment in RZ358 therapy...

Code of Ethics Amendment

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Amendment to Employment Agr...

External Links:

Rezolute, Inc. provided an update on its clinical program for congenital hyperinsulinism, announcing plans to initiate a Phase 3 study in Q4 2023 and reporting $129M in cash and cash equivalents as of March 31, 2023.

AI Assistant

REZOLUTE INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.